Novavax vs BioNTech Which Performs Better?

Novavax and BioNTech are two prominent biotech companies that have been at the forefront of developing innovative vaccines. Novavax is known for its COVID-19 vaccine candidate, NVX-CoV2373, which has shown promising results in clinical trials. On the other hand, BioNTech gained global attention for its partnership with Pfizer in developing the first authorized mRNA COVID-19 vaccine. Both companies have experienced fluctuations in their stock prices due to the competitive nature of the biotech industry and the ongoing COVID-19 pandemic.

Novavax or BioNTech?

When comparing Novavax and BioNTech, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Novavax and BioNTech.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Novavax has a dividend yield of -%, while BioNTech has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Novavax reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, BioNTech reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Novavax P/E ratio at -4.93 and BioNTech's P/E ratio at -56.97. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Novavax P/B ratio is -2.67 while BioNTech's P/B ratio is 1.39.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Novavax has seen a 5-year revenue growth of 4.26%, while BioNTech's is 26.96%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Novavax's ROE at 44.82% and BioNTech's ROE at -2.38%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $8.71 for Novavax and $116.73 for BioNTech. Over the past year, Novavax's prices ranged from $3.53 to $23.86, with a yearly change of 575.92%. BioNTech's prices fluctuated between $76.53 and $131.49, with a yearly change of 71.81%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.